https://www.********.au/2024/02/17/a-hot-asx-stock-with-multiple-catalysts-looming-is-8-down-time-to-buy/ (replace xxxxxx with fool)
A hot ASX stock with 'multiple catalysts' looming is 8% down.
Time to buy
The Blackwattle team is still bullish on these pharmaceutical shares despite a recent sell-off.
It's funny to call an ASX stock that's rocketed 217% in the past year a "bargain".
But that's precisely the situation we have with Neuren Pharmaceuticals Ltd (ASX: NEU), according to the experts at Blackwattle.
Let's check out their rationale:
'A pause for breath'
The Neuren share price has plunged 8.2% since late December.
But the simple fact is that the Blackwattle team is not worried.
"Neuren fell 5% in January, which we saw as a pause for breath, after rising 115% over the previous 3 months," read its memo to clients.
The steep climb in the preceding quarter was due to multiple factors.
"The rise over the previous three months was driven by the release of strong revenue growth from Daybue, their sole approved drug treating Rett Syndrome in the US and positive phase 2 trial results for their new drug NNZ-2591."
The new drug development is critical in the Blackwattle team's continued bullishness.
"The phase 2 results for NNZ-2591 were particularly exciting and provide strong confidence for NNZ-2591 to progress towards a phase 3 trial."
A huge 2024 expected for this ASX stock
Blackwattle experts are far from the only ones not at all put off by either the massive rise in the past year or the diving stock price over the past six weeks.
Broking platform CMC Invest shows all five analysts covering Neuren still rating the stock as a buy.
"We continue to retain a large position in the company given the multiple value accretive upcoming catalysts in 2024," read the memo.
"The key drivers for the portfolio tend to be fundamental company updates which give high quality companies the opportunity to demonstrate their ongoing strength and the market can reassess the outlook and what to pay for it."
Neuren Pharmaceuticals is scheduled to release its preliminary financial results on 23 February.
- Forums
- ASX - By Stock
- Ann: Comment on research report
https://www.********.au/2024/02/17/a-hot-asx-stock-with-multiple-...
-
- There are more pages in this discussion • 145 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.82 |
Change
0.120(0.61%) |
Mkt cap ! $2.530B |
Open | High | Low | Value | Volume |
$19.80 | $19.82 | $18.85 | $6.333M | 324.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 30 | $19.70 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.83 | 1160 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30 | 19.700 |
2 | 1160 | 19.640 |
1 | 846 | 19.630 |
1 | 2648 | 19.620 |
1 | 846 | 19.600 |
Price($) | Vol. | No. |
---|---|---|
19.830 | 1160 | 2 |
19.840 | 846 | 1 |
19.850 | 695 | 1 |
19.870 | 846 | 1 |
19.900 | 3846 | 2 |
Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
$19.74 |
  |
Change
0.120 ( 0.07 %) |
|||
Open | High | Low | Volume | ||
$19.76 | $19.80 | $18.86 | 101075 | ||
Last updated 15.59pm 06/05/2024 ? |
Featured News
NEU (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online